Discover Products, Get Discovered.
Individuals find the right products. Businesses reach the right audience. One platform, free for both.
Individuals find the right products. Businesses reach the right audience. One platform, free for both.
Since 2023, Ohara Pharmaceutical has backed 2 African startups across 3 disclosed funding rounds totaling $39.6M, most heavily in Kenya and Health Tech.
Ohara Pharmaceutical Co., Ltd. is a Japanese pharmaceutical manufacturer specializing in the research, development, manufacture, and distribution of orphan drugs, including anti-cancer drugs and medications for leukemia, as well as high-quality generic medicines. Based in Japan, the company focuses on addressing unmet medical needs in areas such as childhood cancers, central nervous system diseases, and hepatic diseases. It operates with a commitment to providing reliable treatment alternatives from the patient's perspective. Ohara Pharmaceutical has actively invested $39.6 million across three funding rounds from June 2023 to April 2025, targeting health tech companies in Africa. Investments include a $30 million Series B round in Helium Health in Nigeria, which provides digital health records, telemedicine, and clinic financing, and two rounds totaling $9.6 million in MYDAWA in Kenya, a platform for ordering medicines and healthcare essentials with fast delivery. The firm has participated in stages such as Series B, venture (round not specified), and other, with a clear geographic focus on Kenya and Nigeria. The company has co-invested alongside partners including AAIC Investment, Creadev, IFU, and Alta Semper in these African health tech deals.
Data updated · Mar 27, 2026
Ohara Pharmaceutical has backed 2 African startups across 3 disclosed funding rounds tracked on Liners, totaling $39.6M since 2023.
Mostly Venture (Round not Specified): 1 of its 3 tracked rounds are at that stage, followed by Other (1).
Its tracked rounds lean toward Health Tech (3).
Ohara Pharmaceutical most often shares rounds with AAIC Investment (2 shared deals), Creadev (2 shared deals), Investment Fund for Developing Countries (1 shared deal).
Ohara Pharmaceutical has backed Helium Health in Nigeria with a $30 million Series B round in June 2023 and MYDAWA in Kenya with two rounds totaling $9.6 million in April 2025. Both companies focus on health tech solutions like digital records, telemedicine, and medicine delivery.
Ohara Pharmaceutical invested a total of $39.6 million across three funding rounds from June 2023 to April 2025. This includes $30 million in Helium Health and $9.6 million in MYDAWA.
